Detection of aberrant androgen receptor transcripts in circulating tumour cells as a predictor of resistance to AR directed treatment in patients with castration resistant prostate cancer.

The objective of this study is a multi-center clinical validation of a sensitive assay to detect the presence of wild-type (so-called 'full-length') and alternatively spliced variants (ARV) of the androgen receptor (AR) in enriched circulating tumour cells (CTC) of patients with castration-resistant prostate cancer (CRPC). This approach forms an important tool to predict whether or not a patient with CRPC is likely to benefit from a new line hormonal treatment (including but not restricted to e.g. abiraterone acetate and enzalutamide) and thereby contributes to a more personalized treatment approach for this rapidly increasing patient group.

Keywords:PROSTATE CANCER

Disciplines:Morphological sciences, Oncology